STD Treatments Market to Reach Nearly $63.0 2023

September 03, 2018

WELLESLEY, Mass., Sep. 03, 2018–The rising prevalence of diseases and therapeutic aids are two factors helping to boost the global market for the treatment and diagnosis of sexually transmitted diseases, according to a report by BCC Research.

The industry expects to see a compound annual growth rate (CAGR) of 3.9% through 2023, when it could be worth more than $62.9 billion, according to the report Global Market for Treatment and Diagnosis of Sexually Transmitted Diseases.

Major players in the market include Abbott Laboratories, AbbVie, Agilent, Bio-Rad Laboratories, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Hoffman-La Roche, Johnson & Johnson, Merck, Meridian Life Science and Novartis.

Research Highlights

  • Growth will be led by treatments for HIV/AIDS, with an estimated CAGR through 2023 of 4.3%, though by size the market will be led by treatments for Hepatitis B & C, which will have an estimated market value of $30.4 billion.
  • Rapid diagnostics will lead the testing segment by growth and size, with an estimated CAGR of 7.1% and a 2023 value of $4.1 billion, followed by enzyme immunoassay and ELISA, with an estimated CAGR of 6.0% and a 2023 value of $3.5 billion.
  • The hepatitis therapeutics marked will be led in growth by the Asia-Pacific region, with a CAGR through 2023 of 4.9%, though North America will dominate the market by size, with an estimated 2023 value of $13 billion.

“There has been a tremendous increase in the transmission of sexually transmitted infections in all geographies, owing to the asymptomatic nature of these infections, social stigma associated with disease identification, low availability of screening services and less awareness of the disease,” the report notes. “The burden of sexually transmitted infections is often estimated based on diagnostic testing and surveillance of the disease; however, it is usually hampered by the limited availability of diagnostic testing and scarcity of published literature in developing nations.”

STD Stigma and Growing Antibiotic Resistance Joining to Limit Growth

Globally, being identified as a person with a sexually transmitted disease can create unwanted stigma, especially among younger people, and the fear of this stigma can suppress the desire to be tested for a disease. Meanwhile, antibiotics resistance, particularly for the drugs which treat gonorrhea, means that new therapies for treatment are needed.

Editors/reporters requesting analyst interviews should contact Eric Surber at

Global Markets for Treatment and Diagnosis of Sexually Transmitted Diseases( PHM005D )
Publish Date: Aug 2018    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.